Shana E. McCormack
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shana E. McCormack has a total of 417 co-authors. Here are the top co-authors by number of shared publications:
Andrea Kelly
Department of Pediatrics, University of Pennsylvania Perelman School of Medicine , Philadelphia, PA 19104
6 shared publications- Jonathan A. Mitchell
Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA
5 shared publications - Marni J. Falk
Mitochondrial Medicine Frontier Program, Division of Genetic and Genomic Medicine, Children’s Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine, Philadelphia, USA
5 shared publications - Struan F. A. Grant
Department of Genetics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, USA
5 shared publications - Babette S. Zemel
The Perelman School of Medicine at the University of Pennsylvania, Department of Pediatrics , Philadelphia, PA 19104
4 shared publications - David R. Lynch
Departments of Pediatrics and Neurology, The Children's Hospital of Philadelphia, 3401 Civic Center Boulevard, Philadelphia, PA 19104, USA; Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA 19104, USA
4 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (10)
Late recovery from chronic arginine vasopressin deficiency: a multicenter retrospective case-control study
Context: Arginine vasopressin deficiency (AVP-D), caused by hypothalamic/pituitary damage from tumor or surgery, can be transient or chronic. Chronic AVP-D is thought to be permanent though emergent research indicates the possibility of late recovery. Little is known about clinical characteristics that predict late recovery from chronic AVP-D. Objective: Describe characteristics associated with late recovery from chronic AVP-D. Design: Multicenter, retrospective case-control study of AVP-D Recovered (n = 18) vs AVP-D Non-recovered (n = 36; matched for sex and disease duration). Main outcome measures: Clinical characteristics assessed at hypothalamic/pituitary disease diagnosis, AVP-D diagnosis, AVP-D recovery, and most recent clinical evaluation. We also present characteristics of three pediatric cases with AVP-D recovery. Results: At diagnosis of hypothalamic/pituitary disease, AVP-D Recovered, compared to AVP-D Non-recovered, were older (45 ± 19 vs 33 ± 13 years, P = .006) and more likely to have functioning pituitary tumors (33.3% vs 8.3%, P = .05). Following diagnosis of AVP-D, AVP-D Recovered received lower total daily doses of desmopressin (100 [IQR; 50, 100] vs 200 [100, 200] µg oral or equivalent, P = .01). Recovery occurred after a median of 6.3 years [1.7, 12.0] and occurred earlier in those without hypothyroidism (P = .049) or adrenal insufficiency at diagnosis of AVP-D (P = .008). Conclusion: Our study supports the notion that chronic AVP-D may not be permanent across the lifespan. Continued requirement for desmopressin, particularly in those with a history of functioning pituitary tumors, low doses of desmopressin, and without concurrent hypothyroidism or adrenal insufficiency at diagnosis, should be regularly reassessed.
- 3 September 2026
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (10)
Open AccessLate recovery from chronic arginine vasopressin deficiency: a multicenter retrospective case-control study
Context: Arginine vasopressin deficiency (AVP-D), caused by hypothalamic/pituitary damage from tumor or surgery, can be transient or chronic. Chronic AVP-D is thought to be permanent though emergent research indicates the possibility of late recovery. Little is known about clinical characteristics that predict late recovery from chronic AVP-D. Objective: Describe characteristics associated with late recovery from chronic AVP-D. Design: Multicenter, retrospective case-control study of AVP-D Recovered (n = 18) vs AVP-D Non-recovered (n = 36; matched for sex and disease duration). Main outcome measures: Clinical characteristics assessed at hypothalamic/pituitary disease diagnosis, AVP-D diagnosis, AVP-D recovery, and most recent clinical evaluation. We also present characteristics of three pediatric cases with AVP-D recovery. Results: At diagnosis of hypothalamic/pituitary disease, AVP-D Recovered, compared to AVP-D Non-recovered, were older (45 ± 19 vs 33 ± 13 years, P = .006) and more likely to have functioning pituitary tumors (33.3% vs 8.3%, P = .05). Following diagnosis of AVP-D, AVP-D Recovered received lower total daily doses of desmopressin (100 [IQR; 50, 100] vs 200 [100, 200] µg oral or equivalent, P = .01). Recovery occurred after a median of 6.3 years [1.7, 12.0] and occurred earlier in those without hypothyroidism (P = .049) or adrenal insufficiency at diagnosis of AVP-D (P = .008). Conclusion: Our study supports the notion that chronic AVP-D may not be permanent across the lifespan. Continued requirement for desmopressin, particularly in those with a history of functioning pituitary tumors, low doses of desmopressin, and without concurrent hypothyroidism or adrenal insufficiency at diagnosis, should be regularly reassessed.
- Open Access
- 1 September 2026
- Published by Wolters Kluwer Health in Neurology Open Access
- Vol. 2 (3) , e000119
Systemic Metabolomic Changes in Idiopathic Intracranial Hypertension
Background and ObjectivesObesity is a well-established risk factor for idiopathic intracranial hypertension (IIH), yet the metabolic mechanisms linking obesity to IIH remain poorly understood. Prev...
- 1 September 2026
- Published by Wolters Kluwer Health in Neurology Open Access
- Vol. 2 (3) , e000119
Open AccessSystemic Metabolomic Changes in Idiopathic Intracranial Hypertension
Background and ObjectivesObesity is a well-established risk factor for idiopathic intracranial hypertension (IIH), yet the metabolic mechanisms linking obesity to IIH remain poorly understood. Prev...
- Open Access
- 11 May 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (9) , 2692-2703
Approach to the patient with acquired hypothalamic syndrome
The hypothalamus integrates signals from the body and the environment and coordinates homeostatic responses in multiple physiologic processes, including water balance, stress response, temperature regulation, energy balance, feeding behavior, sleep-wake cycles, and reproduction. Endocrinologists care for individuals for whom hypothalamic injury, whether from tumors, their treatment, or other causes, impairs pituitary hormone production and secretion. The extent of other symptoms in affected individuals is also influenced the extent of hypothalamic injury. “Acquired hypothalamic syndrome” refers to this broader collection of problems attributable to hypothalamic injury, variably including not only pituitary hormone deficiencies, but also hypothalamic obesity (or rarely, diencephalic syndrome), sleep and circadian disruption, temperature dysregulation, and behavioral issues (including memory problems and impulse control). Our goal is to present a pragmatic guide to the multidisciplinary, collaborative evaluation and management of hypothalamic syndrome.
- 11 May 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (9) , 2692-2703
Open AccessApproach to the patient with acquired hypothalamic syndrome
The hypothalamus integrates signals from the body and the environment and coordinates homeostatic responses in multiple physiologic processes, including water balance, stress response, temperature regulation, energy balance, feeding behavior, sleep-wake cycles, and reproduction. Endocrinologists care for individuals for whom hypothalamic injury, whether from tumors, their treatment, or other causes, impairs pituitary hormone production and secretion. The extent of other symptoms in affected individuals is also influenced the extent of hypothalamic injury. “Acquired hypothalamic syndrome” refers to this broader collection of problems attributable to hypothalamic injury, variably including not only pituitary hormone deficiencies, but also hypothalamic obesity (or rarely, diencephalic syndrome), sleep and circadian disruption, temperature dysregulation, and behavioral issues (including memory problems and impulse control). Our goal is to present a pragmatic guide to the multidisciplinary, collaborative evaluation and management of hypothalamic syndrome.
- Open Access
- 8 May 2026
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
Geometry of the proximal femur during growth and its contribution to childhood fractures in healthy children
Hip structural analysis (HSA) of proximal femur scans by DXA estimates hip geometry and structural strength, but little is known about how these parameters change during peak bone mass development. We describe age-related changes, precision and long-term stability, and sex and race/ethnic identity differences in hip geometry measures by HSA, and we test whether HSA measures predict childhood fractures in healthy children. We used data from the BMD in Childhood Study, a multi-center, longitudinal cohort study of 2014 healthy US children, ages 5-23 yr, with up to 7 annual visits. Hip structural analysis measures included cortical thickness, cross-sectional area, cross-sectional moment of inertia, section modulus, buckling ratio, and bone width at the narrow neck and femoral shaft, and hip axis length. Additional measures included self-identified race and ethnicity, Z-scores for height, body mass index, appendicular lean soft tissue mass index and fat mass index, and self-reported physical activity, calcium intake, Tanner stage and fractures. Results indicated age-related trends and sex differences in hip geometry. Reference ranges were generated, and HSA Z-scores were adjusted for height-for-age Z-score. Femoral shaft measures showed better precision (coefficient of variation [CV]: 1.1%-3.7%) than narrow neck measures (CV: 2.2%-7.4%); the buckling ratio (both sites) was the least precise. Hip structural analysis Z-scores tracked well over 1 yr (0.77-0.94). Narrow neck buckling ratio (Hazard ratio (HR) 1.16 [95% CI, 1.02, 1.31]) and hip axis length Z-scores (HR 1.20 [95% CI, 1.00, 1.44]) were associated with fracture risk. When adjusted for covariates (BMD Z-score, BMIZ, Tanner stage, and sex), narrow neck cross-sectional area, cross-sectional moment of inertia, section modulus and bone width, and femoral shaft cross-sectional area and section modulus Z-scores positively associated with fractures (eg, section modulus Z-score was associated with a 44% increased fracture risk). These findings provide the foundation for evaluating hip geometry as an indicator of bone strength in children.
- 8 May 2026
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
Open AccessGeometry of the proximal femur during growth and its contribution to childhood fractures in healthy children
Hip structural analysis (HSA) of proximal femur scans by DXA estimates hip geometry and structural strength, but little is known about how these parameters change during peak bone mass development. We describe age-related changes, precision and long-term stability, and sex and race/ethnic identity differences in hip geometry measures by HSA, and we test whether HSA measures predict childhood fractures in healthy children. We used data from the BMD in Childhood Study, a multi-center, longitudinal cohort study of 2014 healthy US children, ages 5-23 yr, with up to 7 annual visits. Hip structural analysis measures included cortical thickness, cross-sectional area, cross-sectional moment of inertia, section modulus, buckling ratio, and bone width at the narrow neck and femoral shaft, and hip axis length. Additional measures included self-identified race and ethnicity, Z-scores for height, body mass index, appendicular lean soft tissue mass index and fat mass index, and self-reported physical activity, calcium intake, Tanner stage and fractures. Results indicated age-related trends and sex differences in hip geometry. Reference ranges were generated, and HSA Z-scores were adjusted for height-for-age Z-score. Femoral shaft measures showed better precision (coefficient of variation [CV]: 1.1%-3.7%) than narrow neck measures (CV: 2.2%-7.4%); the buckling ratio (both sites) was the least precise. Hip structural analysis Z-scores tracked well over 1 yr (0.77-0.94). Narrow neck buckling ratio (Hazard ratio (HR) 1.16 [95% CI, 1.02, 1.31]) and hip axis length Z-scores (HR 1.20 [95% CI, 1.00, 1.44]) were associated with fracture risk. When adjusted for covariates (BMD Z-score, BMIZ, Tanner stage, and sex), narrow neck cross-sectional area, cross-sectional moment of inertia, section modulus and bone width, and femoral shaft cross-sectional area and section modulus Z-scores positively associated with fractures (eg, section modulus Z-score was associated with a 44% increased fracture risk). These findings provide the foundation for evaluating hip geometry as an indicator of bone strength in children.
- Open Access
- 17 April 2026
- Published by Elsevier in The Lancet Neurology
- Vol. 25 (5) , 469-481
Safety and efficacy of individualised exercise and NAD+ precursor supplementation in patients with Friedreich's ataxia in the USA: a single-centre, 2 × 2 factorial, randomised controlled trial
- 17 April 2026
- Published by Elsevier in The Lancet Neurology
- Vol. 25 (5) , 469-481
Open AccessSafety and efficacy of individualised exercise and NAD+ precursor supplementation in patients with Friedreich's ataxia in the USA: a single-centre, 2 × 2 factorial, randomised controlled trial
- 25 March 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (11) , 3034-3048
Race-neutral Pediatric Reference Ranges for Bone Mineral Density Predict Prospective Fractures in Childhood
Introduction: Race-specific reference ranges for pediatric areal bone mineral density (BMD) are widely used, but the value of race-based clinical algorithms has been questioned. We developed race-neutral pediatric reference ranges for areal BMD and bone mineral apparent density (BMAD) and compared race-specific vs race-neutral Z-scores in their ability to predict prospective fractures. Material and Methods: This secondary analysis of the Bone Mineral Density in Childhood Study used longitudinal BMD data of the spine, hip, forearm, and total body less head and BMAD from dual-energy x-ray absorptiometry (DXA) scans. Race/ethnicity, dietary calcium, physical activity, and prospective fractures were assessed by questionnaire. Race-neutral reference ranges and height-for-age Z-score adjustment equations were created using the lambda-sigma-mu method. Race-neutral and race-specific Z-scores were compared using linear mixed-effect modeling. Cox proportional hazard modeling was used to test whether race-neutral Z-scores associated with fracture. Results: Race-neutral BMD and BMAD Z-scores were 0.5 to 0.7 SD greater than race-specific Z-scores for Black children but only ∼0.1 SD lower for children from other race/ethnicity groups. Growth and lifestyle factors modified group differences. One SD increase in race-neutral Z-scores was associated with a 12% to 18% reduced risk of fracture. Conclusion: We present the first race-neutral pediatric reference ranges for BMD and BMAD that are weighted to be representative of the US population and demonstrate that these Z-scores associate with fracture risk. Adoption of these new reference ranges should be considered, with thoughtful implementation for patients previously monitored with race-specific reference ranges, especially among children who identify as Black.
- 25 March 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (11) , 3034-3048
Race-neutral Pediatric Reference Ranges for Bone Mineral Density Predict Prospective Fractures in Childhood
Introduction: Race-specific reference ranges for pediatric areal bone mineral density (BMD) are widely used, but the value of race-based clinical algorithms has been questioned. We developed race-neutral pediatric reference ranges for areal BMD and bone mineral apparent density (BMAD) and compared race-specific vs race-neutral Z-scores in their ability to predict prospective fractures. Material and Methods: This secondary analysis of the Bone Mineral Density in Childhood Study used longitudinal BMD data of the spine, hip, forearm, and total body less head and BMAD from dual-energy x-ray absorptiometry (DXA) scans. Race/ethnicity, dietary calcium, physical activity, and prospective fractures were assessed by questionnaire. Race-neutral reference ranges and height-for-age Z-score adjustment equations were created using the lambda-sigma-mu method. Race-neutral and race-specific Z-scores were compared using linear mixed-effect modeling. Cox proportional hazard modeling was used to test whether race-neutral Z-scores associated with fracture. Results: Race-neutral BMD and BMAD Z-scores were 0.5 to 0.7 SD greater than race-specific Z-scores for Black children but only ∼0.1 SD lower for children from other race/ethnicity groups. Growth and lifestyle factors modified group differences. One SD increase in race-neutral Z-scores was associated with a 12% to 18% reduced risk of fracture. Conclusion: We present the first race-neutral pediatric reference ranges for BMD and BMAD that are weighted to be representative of the US population and demonstrate that these Z-scores associate with fracture risk. Adoption of these new reference ranges should be considered, with thoughtful implementation for patients previously monitored with race-specific reference ranges, especially among children who identify as Black.
- Open Access
- 17 September 2024
- Published by Wiley in Movement Disorders
- Vol. 39 (9) , 1653-1654
Calcitriol in Friedreich Ataxia
- 17 September 2024
- Published by Wiley in Movement Disorders
- Vol. 39 (9) , 1653-1654
Open AccessCalcitriol in Friedreich Ataxia
- Open Access
- 7 August 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (2) , 317-333
Insulin Sensitivity and Insulin Secretion in Adults With Friedreich's Ataxia: The Role of Skeletal Muscle
Introduction Friedreich’s Ataxia (FRDA) is a multi-system disorder caused by frataxin deficiency. FRDA-related diabetes mellitus (DM) is common. Frataxin supports skeletal muscle mitochondrial oxidative phosphorylation (OXPHOS) capacity, a mediator of insulin sensitivity. Our objective was to test the association between skeletal muscle health and insulin sensitivity and secretion in adults with FRDA without DM. Methods Case-control study (NCT02920671). Glucose and insulin metabolism (stable-isotope oral glucose tolerance tests), body composition (dual-energy x-ray absorptiometry), physical activity (self-report), and skeletal muscle OXPHOS capacity (creatine chemical exchange saturation transfer MRI) were assessed. Results Participants included 11 individuals with FRDA (4 female), median age 27y (IQR 23, 39), BMI 26.9kg/m2 (24.1, 29.4), and 24 controls (11 female), 29y (26, 39), 24.4kg/m2 (21.8, 27.0). Fasting glucose was higher in FRDA (91 vs. 83mg/dL (5.0 vs. 4.6mmol/L), p<0.05). Individuals with FRDA had lower insulin sensitivity (WBISI 2.8 vs. 5.3, p<0.01), higher post-prandial insulin secretion (insulin secretory rate iAUC 30-180 minutes, 24,652 vs. 17,858, p<0.05), and more suppressed post-prandial endogenous glucose production (-0.9% vs. 26.9% of fasting EGP, p<0.05). In regression analyses, lower OXPHOS and inactivity explained some of the difference in insulin sensitivity. More visceral fat contributed to lower insulin sensitivity independent of FRDA. Insulin secretion accounting for sensitivity (disposition index) was not different. Conclusions Lower mitochondrial OXPHOS capacity, inactivity, and visceral adiposity contribute to lower insulin sensitivity in FRDA. Higher insulin secretion appears compensatory, and when inadequate, could herald DM. Further studies are needed to determine if muscle- or adipose-focused interventions could delay FRDA-related DM.
- 7 August 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (2) , 317-333
Open AccessInsulin Sensitivity and Insulin Secretion in Adults With Friedreich's Ataxia: The Role of Skeletal Muscle
Introduction Friedreich’s Ataxia (FRDA) is a multi-system disorder caused by frataxin deficiency. FRDA-related diabetes mellitus (DM) is common. Frataxin supports skeletal muscle mitochondrial oxidative phosphorylation (OXPHOS) capacity, a mediator of insulin sensitivity. Our objective was to test the association between skeletal muscle health and insulin sensitivity and secretion in adults with FRDA without DM. Methods Case-control study (NCT02920671). Glucose and insulin metabolism (stable-isotope oral glucose tolerance tests), body composition (dual-energy x-ray absorptiometry), physical activity (self-report), and skeletal muscle OXPHOS capacity (creatine chemical exchange saturation transfer MRI) were assessed. Results Participants included 11 individuals with FRDA (4 female), median age 27y (IQR 23, 39), BMI 26.9kg/m2 (24.1, 29.4), and 24 controls (11 female), 29y (26, 39), 24.4kg/m2 (21.8, 27.0). Fasting glucose was higher in FRDA (91 vs. 83mg/dL (5.0 vs. 4.6mmol/L), p<0.05). Individuals with FRDA had lower insulin sensitivity (WBISI 2.8 vs. 5.3, p<0.01), higher post-prandial insulin secretion (insulin secretory rate iAUC 30-180 minutes, 24,652 vs. 17,858, p<0.05), and more suppressed post-prandial endogenous glucose production (-0.9% vs. 26.9% of fasting EGP, p<0.05). In regression analyses, lower OXPHOS and inactivity explained some of the difference in insulin sensitivity. More visceral fat contributed to lower insulin sensitivity independent of FRDA. Insulin secretion accounting for sensitivity (disposition index) was not different. Conclusions Lower mitochondrial OXPHOS capacity, inactivity, and visceral adiposity contribute to lower insulin sensitivity in FRDA. Higher insulin secretion appears compensatory, and when inadequate, could herald DM. Further studies are needed to determine if muscle- or adipose-focused interventions could delay FRDA-related DM.
- Open Access
- 18 July 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (16)
NAD+ precursors prolong survival and improve cardiac phenotypes in a mouse model of Friedreich’s Ataxia
Friedreich’s ataxia (FRDA) is a progressive disorder caused by insufficient expression of frataxin, which plays a critical role in assembly of iron-sulfur centers in mitochondria. Individuals are cognitively normal but display a loss of motor coordination and cardiac abnormalities. Many ultimately develop heart failure. Administration of nicotinamide adenine dinucleotide–positive (NAD + ) precursors has shown promise in human mitochondrial myopathy and rodent models of heart failure, including mice lacking frataxin in cardiomyocytes. We studied mice with systemic knockdown of frataxin (shFxn), which display motor deficits and early mortality with cardiac hypertrophy. Hearts in these mice do not “fail” per se but become hyperdynamic with small chamber sizes. Data from an ongoing natural history study indicate that hyperdynamic hearts are observed in young individuals with FRDA, suggesting that the mouse model could reflect early pathology. Administering nicotinamide mononucleotide or riboside to shFxn mice increases survival, modestly improves cardiac hypertrophy, and limits increases in ejection fraction. Mechanistically, most of the transcriptional and metabolic changes induced by frataxin knockdown are insensitive to NAD + precursor administration, but glutathione levels are increased, suggesting improved antioxidant capacity. Overall, our findings indicate that NAD + precursors are modestly cardioprotective in this model of FRDA and warrant further investigation.
- 18 July 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (16)
Open AccessNAD+ precursors prolong survival and improve cardiac phenotypes in a mouse model of Friedreich’s Ataxia
Friedreich’s ataxia (FRDA) is a progressive disorder caused by insufficient expression of frataxin, which plays a critical role in assembly of iron-sulfur centers in mitochondria. Individuals are cognitively normal but display a loss of motor coordination and cardiac abnormalities. Many ultimately develop heart failure. Administration of nicotinamide adenine dinucleotide–positive (NAD + ) precursors has shown promise in human mitochondrial myopathy and rodent models of heart failure, including mice lacking frataxin in cardiomyocytes. We studied mice with systemic knockdown of frataxin (shFxn), which display motor deficits and early mortality with cardiac hypertrophy. Hearts in these mice do not “fail” per se but become hyperdynamic with small chamber sizes. Data from an ongoing natural history study indicate that hyperdynamic hearts are observed in young individuals with FRDA, suggesting that the mouse model could reflect early pathology. Administering nicotinamide mononucleotide or riboside to shFxn mice increases survival, modestly improves cardiac hypertrophy, and limits increases in ejection fraction. Mechanistically, most of the transcriptional and metabolic changes induced by frataxin knockdown are insensitive to NAD + precursor administration, but glutathione levels are increased, suggesting improved antioxidant capacity. Overall, our findings indicate that NAD + precursors are modestly cardioprotective in this model of FRDA and warrant further investigation.
- 22 May 2023
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 77 (6) , e152-e153
Gender Disparities in Abstracts Presented at the Vascular Annual Meeting Differ Between the First and Last Authors
- 22 May 2023
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 77 (6) , e152-e153
Gender Disparities in Abstracts Presented at the Vascular Annual Meeting Differ Between the First and Last Authors